<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>17(11)</volume><submitter>Baumert BG</submitter><funding>Cancer Research UK</funding><funding>Medical Research Council</funding><funding>NCI NIH HHS</funding><funding>National Health and MRC project grant</funding><funding>Canadian Cancer Society Research Institute</funding><journal>The Lancet. Oncology</journal><pagination>1521-1532</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5124485</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.</pubmed_title><pmcid>PMC5124485</pmcid><funding_grant_id>MC_UU_12023/10</funding_grant_id><funding_grant_id>MC_U122861383</funding_grant_id><funding_grant_id>6850</funding_grant_id><funding_grant_id>U10 CA011488</funding_grant_id><funding_grant_id>MC_UU_12023/20</funding_grant_id><funding_grant_id>ID 509094</funding_grant_id><funding_grant_id>grant number 015469 and 021039</funding_grant_id><funding_grant_id>MC_UU_12023/28</funding_grant_id><pubmed_authors>Thiessen B</pubmed_authors><pubmed_authors>Dhermain F</pubmed_authors><pubmed_authors>Kantor G</pubmed_authors><pubmed_authors>Bravo-Marques J</pubmed_authors><pubmed_authors>Rees J</pubmed_authors><pubmed_authors>Reni M</pubmed_authors><pubmed_authors>Gijtenbeek JMM</pubmed_authors><pubmed_authors>Clement PM</pubmed_authors><pubmed_authors>Rossiter JP</pubmed_authors><pubmed_authors>Kros JM</pubmed_authors><pubmed_authors>Feuvret L</pubmed_authors><pubmed_authors>Mason WP</pubmed_authors><pubmed_authors>Hoang-Xuan K</pubmed_authors><pubmed_authors>Brandes AA</pubmed_authors><pubmed_authors>Chinot O</pubmed_authors><pubmed_authors>Reijneveld JC</pubmed_authors><pubmed_authors>Dif N</pubmed_authors><pubmed_authors>Enting R</pubmed_authors><pubmed_authors>van den Bent MJ</pubmed_authors><pubmed_authors>von Deimling A</pubmed_authors><pubmed_authors>Hassel MB</pubmed_authors><pubmed_authors>Hartmann C</pubmed_authors><pubmed_authors>Hegi ME</pubmed_authors><pubmed_authors>Capper D</pubmed_authors><pubmed_authors>Kurscheid S</pubmed_authors><pubmed_authors>Lacombe D</pubmed_authors><pubmed_authors>Balana C</pubmed_authors><pubmed_authors>Tzuk-Shina T</pubmed_authors><pubmed_authors>Baumert BG</pubmed_authors><pubmed_authors>Wick W</pubmed_authors><pubmed_authors>Stupp R</pubmed_authors><pubmed_authors>Taphoorn MJB</pubmed_authors><pubmed_authors>Marosi C</pubmed_authors><pubmed_authors>Gorlia T</pubmed_authors><pubmed_authors>Bromberg JE</pubmed_authors><pubmed_authors>Nordal RA</pubmed_authors><pubmed_authors>Ryan G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.</name><description/><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Nov</publication><modification>2026-05-03T02:18:01.339Z</modification><creation>2025-02-19T00:46:37.772Z</creation></dates><accession>S-EPMC5124485</accession><cross_references><pubmed>27686946</pubmed><doi>10.1016/S1470-2045(16)30313-8</doi></cross_references></HashMap>